Mario Schlosser Sells 38,835 Shares of Oscar Health (NYSE:OSCR) Stock

by · The Cerbat Gem

Oscar Health, Inc. (NYSE:OSCR – Get Free Report) insider Mario Schlosser sold 38,835 shares of the stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $15.00, for a total transaction of $582,525.00. Following the completion of the transaction, the insider owned 438,348 shares in the company, valued at $6,575,220. This trade represents a 8.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mario Schlosser also recently made the following trade(s):

  • On Tuesday, December 2nd, Mario Schlosser sold 23,965 shares of Oscar Health stock. The shares were sold at an average price of $16.59, for a total value of $397,579.35.
  • On Tuesday, November 11th, Mario Schlosser sold 286,182 shares of Oscar Health stock. The stock was sold at an average price of $15.27, for a total value of $4,369,999.14.

Oscar Health Price Performance

Shares of OSCR stock traded down $0.03 on Tuesday, hitting $14.50. 4,909,284 shares of the stock traded hands, compared to its average volume of 14,119,056. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.92 and a quick ratio of 0.92. Oscar Health, Inc. has a 52 week low of $11.20 and a 52 week high of $23.80. The firm has a 50 day simple moving average of $16.46 and a two-hundred day simple moving average of $17.07. The firm has a market cap of $3.84 billion, a price-to-earnings ratio of -12.94 and a beta of 1.88.

Oscar Health (NYSE:OSCR – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. Oscar Health had a negative return on equity of 21.50% and a negative net margin of 2.16%.The firm had revenue of $2.93 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same quarter last year, the business posted ($0.22) earnings per share. The firm’s revenue was up 23.2% on a year-over-year basis. As a group, equities research analysts predict that Oscar Health, Inc. will post 0.69 earnings per share for the current fiscal year.

Institutional Trading of Oscar Health

A number of institutional investors have recently modified their holdings of the company. Thrive Capital Management LLC grew its stake in shares of Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after purchasing an additional 1,588,395 shares during the period. Raymond James Financial Inc. boosted its stake in shares of Oscar Health by 1.0% during the 1st quarter. Raymond James Financial Inc. now owns 497,143 shares of the company’s stock worth $6,518,000 after acquiring an additional 5,097 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Oscar Health by 2.7% during the 1st quarter. Hsbc Holdings PLC now owns 24,113 shares of the company’s stock valued at $313,000 after acquiring an additional 632 shares during the period. Corebridge Financial Inc. raised its holdings in Oscar Health by 1.1% in the 1st quarter. Corebridge Financial Inc. now owns 100,119 shares of the company’s stock worth $1,313,000 after purchasing an additional 1,087 shares during the period. Finally, Ieq Capital LLC boosted its position in Oscar Health by 34.6% during the first quarter. Ieq Capital LLC now owns 20,344 shares of the company’s stock worth $267,000 after purchasing an additional 5,234 shares in the last quarter. 75.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OSCR. Zacks Research raised shares of Oscar Health from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th. Stephens began coverage on Oscar Health in a research note on Thursday, December 11th. They set an “equal weight” rating and a $17.00 target price on the stock. Barclays increased their price target on Oscar Health from $11.00 to $13.00 and gave the stock an “underweight” rating in a report on Monday, November 10th. Piper Sandler upgraded Oscar Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $13.00 to $25.00 in a report on Tuesday, November 25th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Oscar Health in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $15.57.

Check Out Our Latest Analysis on Oscar Health

Oscar Health Company Profile

(Get Free Report)

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

Featured Articles